eFFECTOR Therapeutics Future Growth

Future criteria checks 0/6

eFFECTOR Therapeutics is forecast to grow earnings at 1.1% per annum. EPS is expected to decline by 68.6% per annum.

Key information

1.1%

Earnings growth rate

-68.6%

EPS growth rate

Biotechs earnings growth	42.4%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	Low
Last updated	20 Feb 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

BST:LWK1 - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	N/A	-36	-31	N/A	1
12/31/2024	N/A	-33	-26	N/A	2
12/31/2023	N/A	-36	N/A	N/A	N/A
9/30/2023	1	-36	-31	-31	N/A
6/30/2023	2	-37	-31	-31	N/A
3/31/2023	4	-36	-27	-27	N/A
12/31/2022	4	-23	-26	-26	N/A
9/30/2022	3	6	-24	-24	N/A
6/30/2022	3	24	-25	-25	N/A
3/31/2022	1	25	-26	-26	N/A
12/31/2021	1	16	-25	-25	N/A
9/30/2021	1	-4	-28	-27	N/A
6/30/2021	1	-20	-26	-26	N/A
3/31/2021	16	-7	-8	-8	N/A
12/31/2020	42	0	14	14	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: LWK1 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: LWK1 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: LWK1 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if LWK1's revenue is forecast to grow faster than the German market.

High Growth Revenue: LWK1 is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if LWK1's Return on Equity is forecast to be high in 3 years time

eFFECTOR Therapeutics Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

eFFECTOR Therapeutics Files Form 15

eFFECTOR Therapeutics, Inc.(OTCPK:EFTR) dropped from NASDAQ Composite Index

eFFECTOR Therapeutics Provides Non-Compliance Update

eFFECTOR Therapeutics Plans to Voluntarily Request a Delisting of its Securities and Expects its Securities to be Delisted in the Near Term

eFFECTOR Therapeutics, Inc. Receives Written Notice from Nasdaq Regarding Minimum Value of Listed Securities

eFFECTOR Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

eFFECTOR Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

eFFECTOR Therapeutics, Inc. Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer

eFFECTOR Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $15.000003 million.

eFFECTOR Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $15.000003 million.

eFFECTOR Therapeutics, Inc. Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in Er+ Metastatic Breast Cancer Patients

eFFECTOR Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of Er+/Her2- Advanced Metastatic Breast Cancer

Effector Therapeutics, Inc. Announces Initiation of Dosing in an Investigator-Initiated Phase 1 Dose Escalation Trial Evaluating Tomivosertib in Patients with Relapsed/Refractory Acute Myeloid Leukemia (Aml)

eFFECTOR Therapeutics, Inc. Appoints Caroline Loewy to its Board of Directors

eFFECTOR Therapeutics Receives Non-Compliance Notice from Nasdaq Stock Market Regarding Non-Compliance with Nasdaq's Minimum Bid Price Requirement

eFFECTOR Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $8.733186 million.

eFFECTOR Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $7.49325 million.

eFFECTOR Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $7.49325 million.

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies